BML Capital Management, LLC 13F Holdings · Q2 2026
BML Capital Management, LLC reported 15 securities worth $176.05M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ACRS (35.98%), AVIR (18.36%), ENGN (6.55%). Among its top 25 positions this quarter: 3 new, 5 added, 3 trimmed, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ACRS | ACLARIS THERAPEUTICS INC | $63.3M | 35.98% | 12.0M | Trimmed |
| 2 | AVIR | ATEA PHARMACEUTICALS INC | $32.3M | 18.36% | 7.0M | Trimmed |
| 3 | ENGN | ENGENE THERAPEUTICS INC | $11.5M | 6.55% | 6.7M | New |
| 4 | KHC | KRAFT HEINZ CO | $11.0M | 6.24% | 465,000 | Added |
| 5 | OM | OUTSET MED INC | $10.9M | 6.18% | 2.5M | Added |
| 6 | KMX | CARMAX INC | $9.1M | 5.18% | 172,500 | Added |
| 7 | TLYS | TILLYS INC | $9.0M | 5.13% | 2.1M | Hold |
| 8 | PMVP | PMV PHARMACEUTICALS INC | $7.1M | 4.06% | 5.3M | Added |
| 9 | TIL | INSTIL BIO INC | $5.0M | 2.82% | 645,600 | Hold |
| 10 | TGT | TARGET CORP | $4.9M | 2.78% | 37,500 | Hold |
| 11 | ORMP | ORAMED PHARMACEUTICALS INC | $4.2M | 2.37% | 866,269 | Trimmed |
| 12 | JANX | JANUX THERAPEUTICS INC | $2.4M | 1.35% | 154,961 | Hold |
| 13 | PLRX | PLIANT THERAPEUTICS INC | $1.8M | 1.00% | 1.5M | Hold |
| 14 | CNTB | CONNECT BIOPHARMA HLDGS LTD | $1.4M | 0.78% | 573,287 | Added |
| 15 | IMA | IMAGENEBIO INC | $1.2M | 0.67% | 200,730 | Hold |
| 16 | WMT | WALMART INC | $386,088 | 0.22% | 335 | Hold |
| 17 | CORZ | CORE SCIENTIFIC INC NEW | $298,000 | 0.17% | 800 | New |
| 18 | TSLA | TESLA INC | $270,000 | 0.15% | 375 | New |
| 19 | KZR | KEZAR LIFE SCIENCES INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR